Propafenone—Clinical Electrophysiology and Efficacy in Patients with Documented or Potentially Life‐threatening Arrhythmias

Propafenone is a new antiarrhythmic agent that inhibits the fast sodium channel and decreases phase 0 of the cardiac action potential. Since it has relatively little effect on the action potential duration, it has been classified as a type IC agent. Propafenone prolongs electrocardiographic intervals including PR and QRS. In addition, atrial and ventricular refractory periods generally are lengthened. Initial reports suggest a favorable effect on suppressing conduction over accessory pathways. Propafenone has been shown to have effectiveness in suppressing life‐threatening ventricular arrhythmias as well. Electrophysiological testing is useful, but data such as mode of induction and rate of induced tachycardia should be considered in addition to inducibility status.